ReportWire

Tag: Regeneron Pharmaceuticals Inc.

  • Cramer's week ahead: Earnings season kicks off after JPMorgan Healthcare Conference

    Cramer's week ahead: Earnings season kicks off after JPMorgan Healthcare Conference

    [ad_1]

    CNBC’s Jim Cramer on Friday told investors what to watch for on Wall Street next week, highlighting JPMorgan‘s market-moving health-care conference in San Francisco. Taking place from Monday to Thursday, the conference is one of the year’s largest gatherings of major industry CEOs where they reveal earnings guidance and updates on clinical trial research.

    “The new year has started with a redistribution of cash out of the ‘Magnificent Seven’ and on to the sidelines,” Cramer said, pointing to health-care stocks as a particularly notable group that will likely be “propelled by what people expect to hear from the JPMorgan Healthcare Conference.”

    Cramer will interview several CEOs at the conference, starting with Walgreens CEO Tim Wentworth on Monday. Cramer said he’s interested to hear how the company plans to get its groove back after cutting its dividend nearly in half this week. Cramer will also speak with leadership from Amgen and Medtronic, as well as the new CEO of Bristol Myers, Chris Boerner, whom he’ll ask about the company’s rigorous biotech acquisition plans.

    On Tuesday and Wednesday, Cramer will continue to interview the CEOs of major industry names, including Eli Lilly CEO David Ricks. Cramer said he’s particularly interested in the company’s diabetes and weight loss drug as well as its Alzheimer’s initiative. He’ll also speak with CVS Health CEO Karen S. Lynch to discuss the company’s ongoing transition from drug store to health-care provider. Cramer will also hear from the CEOs of Pfizer, Regeneron, Novartis, Abbott Labs and Cencora.

    Thursday brings the consumer price index for December. Cramer said he thinks those hoping for soft figures will be disappointed. Cramer will also be tuning into CES, the Consumer Electronics Show, next week. The tech event will include commentary by leadership from Nvidia and Dell.

    Earnings season kicks off Friday with reports from major banks including JPMorgan, Bank of America and Wells Fargo. BlackRock will also report, and Cramer said he thinks the company’s earnings could give investors a solid overview of the financial industry. He’ll also be paying attention to Friday reports from UnitedHealth Group and Delta.

    Jim Cramer talks what's ahead for the markets next week

    Jim Cramer’s Guide to Investing

    Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

    Disclaimer The CNBC Investing Club Charitable Trust holds shares of Eli Lilly.

    Questions for Cramer?
    Call Cramer: 1-800-743-CNBC

    Want to take a deep dive into Cramer’s world? Hit him up!
    Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram

    Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

    [ad_2]

    Source link

  • Here are Wednesday's biggest analyst calls: Tesla, Walmart, Qualcomm, Deere, Robinhood, Shopify & more

    Here are Wednesday's biggest analyst calls: Tesla, Walmart, Qualcomm, Deere, Robinhood, Shopify & more

    [ad_1]

    [ad_2]

    Source link

  • Regeneron shares fall after FDA rejects high-dose eye disease treatment

    Regeneron shares fall after FDA rejects high-dose eye disease treatment

    [ad_1]

    A view of the Regeneron Pharmaceuticals headquarters in Tarrytown, New York.

    Lev Radin | LightRocket | Getty Images

    Shares of Regeneron fell nearly 9% Tuesday after the U.S. Food and Drug Administration declined to approve a higher-dose version of the company’s blockbuster eye disease treatment.

    The company was seeking approval for an 8-milligram dose of its injection, Eylea, for patients with wet age-related macular degeneration — the leading cause of blindness among the elderly — and two other eye diseases that are common in people with diabetes. 

    Regeneron said the rejection was “solely due to an ongoing review of inspection findings at a third-party filler.”

    The company did not provide further details on those findings or identify the third party, but said the decision was not related to the drug’s efficacy, safety, trial design, labeling or drug substance manufacturing. 

    That suggests the drug could potentially win approval down the road. 

    But a delay won’t help the company fight off threats to its Eylea drug franchise, which is facing competition from Roche Holdings‘ eye drug, Vabysmo. Roche’s treatment was approved last year.

    Stock Chart IconStock chart icon

    Regeneron stock fell nearly 9% Tuesday after an FDA rejection of a higher-dose version of the company’s blockbuster eye treatment.

    [ad_2]

    Source link

  • Cramer’s week ahead: Fed decision on Wednesday could let the bulls ‘party on’

    Cramer’s week ahead: Fed decision on Wednesday could let the bulls ‘party on’

    [ad_1]

    CNBC’s Jim Cramer on Friday said that Wall Street’s recent gains could continue next week depending on the Federal Reserve’s actions.

    “A decision not to raise rates at all might show too much weakness. A quarter-point with a statement that they’ll remain vigilant will allow the bulls to party on,” he said.

    The central bank is set to conclude its first meeting of the year on Wednesday, which Wall Street largely expected to beget a quarter-percentage point interest rate hike. 

    Cramer said he’ll also have his eye on the January nonfarm payrolls report set to be released Friday. “If wage inflation’s very strong, the quarter-point move will be criticized. If it’s weaker, we’ll be hearing all about that hard landing,” he said.

    All estimates for earnings, revenue and economic data are courtesy of FactSet.

    Monday: Whirlpool

    • Q4 2022 earnings release at 4:05 p.m. ET; conference call on Tuesday at 8 a.m. ET
    • Projected EPS: $3.23
    • Projected revenue: $5.08 billion

    He predicted that the company will report abating supply chain headwinds and a more frugal consumer on its conference call.

    Tuesday: Caterpillar, Pfizer, Advanced Micro Devices

    Caterpillar

    • Q4 2022 earnings release at 6:30 a.m. ET; conference call at 8:30 a.m. ET
    • Projected EPS: $4.02
    • Projected revenue; $15.82 billion

    He said the company will likely report a solid quarter.

    Pfizer

    • Q4 2022 earnings release at 6:45 a.m. ET; conference call at 10 a.m. ET
    • Projected EPS: $1.05
    • Projected revenue: $24.44 billion

    There’s more to the company than unsustainable earnings from its Covid vaccine, despite what Wall Street believes, Cramer said.

    Advanced Micro Devices

    • Q4 2022 earnings release at 4:15 p.m. ET; conference call at 5 p.m. ET
    • Projected EPS: 67 cents
    • Projected revenue: $5.51 billion

    “AMD’s got a great portfolio now, and they keep taking market share,” he said.

    Wednesday: Meta Platforms

    • Q4 2022 earnings release at 4:05 p.m. ET; conference call at 5 p.m. ET
    • Projected EPS: $2.26
    • Projected revenue: $31.54 billion

    “All I know is the stock’s had a real run, and while we own it for the Charitable Trust, we’re not pounding the table on this one. Not here,” Cramer said.

    Thursday: Ford Motor, Apple, Amazon, Alphabet

    Ford

    • Q4 2022 earnings release at 4:05 p.m. ET; conference call at 5 p.m. ET
    • Projected EPS: 62 cents
    • Projected revenue: $41.39 billion

    He said he isn’t worried that price cuts from Tesla will affect demand for Ford’s electric vehicles.

    Apple

    • Q1 21023 earnings release at 4:30 p.m. ET; conference call at 5 p.m. ET
    • Projected EPS: $1.94
    • Projected revenue: $121.81 billion

    Investors should hold onto their shares of the iPhone maker, according to Cramer.

    Amazon

    • Q4 2022 earnings release at 4:01 p.m. ET; conference call at 5:30 p.m. ET
    • Projected EPS: 17 cents
    • Projected revenue: $145.64 billion

    Amazon stock will soar if the company lays off 100,000 employees, he predicted.

    Alphabet

    • Q4 2022 earnings release at 4 p.m. ET; conference call at 4:30 p.m. ET
    • Projected EPS: $1.18
    • Projected revenue: $76.17 billion

    Cramer said that Alphabet also needs to downsize its workforce.

    Friday: Regeneron Pharmaceuticals

    • Q4 2022 earnings release at 6:30 a.m. ET; conference call at 8:30 a.m. ET
    • Projected EPS: $10.1
    • Projected revenue: $3.14 billion

    He said he likes the stock.

    Disclaimer; Cramer’s Charitable Trust owns shares of Apple, Amazon, Advanced Micro Devices, Caterpillar, Ford and Meta.

    Cramer's game plan for the trading week of Jan. 30

    Jim Cramer’s Guide to Investing

    Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.

    [ad_2]

    Source link

  • This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    This fund beats the S&P 500 by using just 75 of its components. Here’s how it works.

    [ad_1]

    What worked well during the years-long bull market through 2021 — a focus on growth, regardless of price — has ground to a halt this year. The rebirth of the value style of investing — and modest valuations overall — has taken hold.

    The approach taken by the Invesco S&P 500 GARP ETF has paid off through both bull and bear markets.

    Let’s begin with a 10-year chart comparing total returns with dividends reinvested for the Invesco S&P 500 GARP ETF
    SPGP,
    +0.67%
    and the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%    ,
    which tracks the benchmark S&P 500:


    FactSet

    So far this year, SPGP is down 12%, while SPY is down 16%. But the long-term chart shows significant and consistent outperformance for SPGP, even during the bull market.

    The S&P 500 GARP Index

    GARP stands for “growth at a reasonable price.” SPGP tracks the S&P 500 GARP Index, which is reconstituted and rebalanced twice a year, on the third Fridays of June and December. The next change occurs Dec. 16.

    S&P Dow Jones Indices assigns a growth score to each component of the S&P 500 by averaging the three-year compound annual growth rate (CAGR) for earnings and sales per share.

    The top 150 components of the S&P 500 by growth score are eligible for inclusion in the GARP index. Those 150 are ranked by “quality/value composite score,” which is the average of these three ratios:

    • Financial leverage — total debt to book value.

    • Return on equity — trailing 12 months’ earnings per share divided by book value per share.

    • Earnings-to-price — 12 months’ earnings per share divided by the share price.

    The top 75 of the 150 by QV rankings are then included in the GARP index and weighted by the growth score, with portfolio weightings ranging from 0.5% to 5%.

    There is a weighting limitation of 40% to any one of the 11 S&P sectors.

    Addressing concentration risk

    The benchmark S&P 500 Index
    SPX,
    +0.75%
    is weighted by market capitalization, which means it is more heavily concentrated than you might expect — success is rewarded, with rising stocks more heavily weighted over time.

    That can backfire during a bear market, with Amazon.com Inc.
    AMZN,
    +2.14%
    down 47% and Tesla Inc.
    TSLA,
    -0.34%
    down 51% this year, to name two prominent examples.

    Looking at the SPDR S&P 500 ETF Trust
    SPY,
    +0.78%    ,
    which is the first and largest exchange traded fund and tracks the benchmark index by holding all of its components, six companies (Apple Inc.
    AAPL,
    +1.21%    ,
    Microsoft Corp.
    MSFT,
    +1.24%    ,
    Amazon, both common share classes of Alphabet Inc.
    GOOGL,
    -1.30%
     
    GOOG,
    -1.26%
    and Berkshire Hathaway Inc.
    BRK.B,
    +0.06%
    ) make up 19.2% of the portfolio.

    That percentage has come down this year, but a lot of risk remains concentrated in a handful of companies. (Apple alone makes up 6.4% of the SPY portfolio. Tesla is now the ninth-largest holding, making up 1.4% of the portfolio.)

    One way to address high concentration in an index fund is to use an equal-weighted approach, which Mark Hulbert recently discussed.

    For the Invesco S&P 500 GARP ETF, the underlying index’s selection methodology has resulted in much less portfolio concentration than we see in SPY, with the top five holdings making up 10.9% of the portfolio.

    Here are the 10 largest holdings of SPGP:

    Company

    		 Ticker

    		 Share of portfolio
    Regeneron Pharmaceuticals, Inc.

    		 REGN,
    +0.15%         		2.49%
    Cigna Corporation

    		 CI,
    +0.39%         		2.26%
    Everest Re Group, Ltd.

    		 RE,
    +0.24%         		2.21%
    Vertex Pharmaceuticals Incorporated

    		 VRTX,
    +1.18%         		1.98%
    D.R. Horton, Inc.

    		 DHI,
    -0.39%         		1.97%
    Expeditors International of Washington, Inc.

    		 EXPD,
    +0.23%         		1.96%
    Incyte Corporation

    		 INCY,
    +0.10%         		1.92%
    Goldman Sachs Group, Inc.

    		 GS,
    -0.51%         		1.83%
    Ebay Inc.

    		 EBAY,
    +1.67%         		1.81%
    Pfizer Inc.

    		 PFE,
    +3.07%         		1.73%
    Source: FactSet

    Click on the tickers for more information about any company, ETF or index in this article.

    You should also read Tomi Kilgore’s detailed guide to the wealth of information for free on the MarketWatch quote page.

    Don’t miss: 10 Dividend Aristocrat stocks expected by analysts to rise up to 54% in 2023

    [ad_2]

    Source link